National Bank of Canada FI Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

National Bank of Canada FI cut its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 41.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 290,100 shares of the medical research company’s stock after selling 206,948 shares during the period. National Bank of Canada FI owned approximately 0.08% of Thermo Fisher Scientific worth $117,622,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. Front Row Advisors LLC grew its holdings in Thermo Fisher Scientific by 0.7% in the 2nd quarter. Front Row Advisors LLC now owns 5,835 shares of the medical research company’s stock valued at $2,368,000 after buying an additional 39 shares in the last quarter. FORA Capital LLC boosted its position in shares of Thermo Fisher Scientific by 100.7% during the 2nd quarter. FORA Capital LLC now owns 3,965 shares of the medical research company’s stock valued at $1,608,000 after acquiring an additional 1,989 shares during the last quarter. Headlands Technologies LLC grew its holdings in shares of Thermo Fisher Scientific by 114.3% in the second quarter. Headlands Technologies LLC now owns 13,360 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 7,127 shares during the period. CANADA LIFE ASSURANCE Co raised its stake in Thermo Fisher Scientific by 10.8% during the second quarter. CANADA LIFE ASSURANCE Co now owns 528,654 shares of the medical research company’s stock worth $214,630,000 after purchasing an additional 51,692 shares during the period. Finally, Duquesne Family Office LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at about $4,947,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 10,225 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the sale, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. This represents a 41.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the sale, the executive vice president directly owned 14,367 shares in the company, valued at $8,586,868.56. This represents a 32.49% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 149,271 shares of company stock valued at $86,507,282 in the last 90 days. Insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on TMO shares. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a research report on Tuesday, September 2nd. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. Evercore ISI raised their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Thursday, October 23rd. Finally, KeyCorp upgraded shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target for the company in a research report on Sunday, December 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $614.60.

Thermo Fisher Scientific Stock Down 1.2%

Shares of NYSE:TMO opened at $572.03 on Monday. The firm has a market capitalization of $214.92 billion, a PE ratio of 33.05, a price-to-earnings-growth ratio of 4.18 and a beta of 0.90. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The firm’s 50-day moving average is $565.86 and its two-hundred day moving average is $492.20.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business’s quarterly revenue was up 4.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.94%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.